{"id":666979,"date":"2026-10-27T16:50:09","date_gmt":"2026-10-27T16:50:09","guid":{"rendered":"https:\/\/www.newsbeep.com\/ie\/666979\/"},"modified":"2026-10-27T16:50:09","modified_gmt":"2026-10-27T16:50:09","slug":"idsa-2026-guidance-makes-sulbactam-durlobactam-the-priority-for-crab-infections","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ie\/666979\/","title":{"rendered":"IDSA 2026 Guidance Makes Sulbactam-Durlobactam the Priority for CRAB Infections"},"content":{"rendered":"\n<p class=\"\">David Altarac, MD, chief medical officer at Innoviva Specialty Therapeutics, which markets sulbactam-durlobactam in the United States, spoke with Contagion at <a href=\"https:\/\/www.contagionlive.com\/conference\/idweek\" target=\"_blank\" rel=\"nofollow noopener\">IDWeek 2026<\/a> in Washington, DC, about the guidance update and its implications for CRAB treatment decisions.\u00b3<\/p>\n<p class=\"\">Contagion: The 2026 IDSA guidance makes sulbactam-durlobactam the priority for invasive CRAB infections. What are the key takeaways for clinicians?<\/p>\n<p class=\"\">David Altarac, MD: Sulbactam-durlobactam, or Xacduro, was approved in the US in 2023 for the treatment of hospital-acquired and ventilator-associated pneumonias due to Acinetobacter infections in adults. Carbapenem-resistant Acinetobacter infections have historically been very difficult to treat, with limited treatment options. <\/p>\n<p class=\"\">Shortly after approval, IDSA issued its guidance and identified Xacduro, along with a carbapenem, as a preferred treatment for carbapenem-resistant Acinetobacter. The recently updated guidance again identifies Xacduro as a first-line agent, in combination with a carbapenem, as the preferred treatment option for invasive CRAB infections. This represents a shift from relying on limited options toward a therapy designed to address the organism\u2019s resistance mechanism, and is an important advancement in how we make treatment decisions.<\/p>\n<p class=\"\">Editor\u2019s Note: This transcript has been edited for grammar and clarity using artificial intelligence tools.<\/p>\n<p class=\"\">Check out the first episode of the ID Week interview with Altarac: <br \/><a href=\"https:\/\/www.contagionlive.com\/view\/zoliflodacin-holds-gonorrhea-cure-rates-in-chlamydia-coinfected-patients\" target=\"_blank\" rel=\"nofollow noopener\">Zoliflodacin Holds Gonorrhea Cure Rates in Chlamydia Coinfected Patients<\/a><\/p>\n<p>REFERENCES:Infectious Diseases Society of America. IDSA 2026 guidance on the treatment of antimicrobial-resistant gram-negative infections. Published July 30, 2026. Accessed October 26, 2026. <a href=\"https:\/\/www.idsociety.org\/practice-guideline\/amr-guidance\/\" rel=\"nofollow noreferrer noopener\" target=\"_self\">https:\/\/www.idsociety.org\/practice-guideline\/amr-guidance\/<\/a>Kaye KS, Shorr AF, Wunderink RG, et al. Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK). Lancet Infect Dis. 2023;23(9):1072-1084. doi:10.1016\/S1473-3099(23)00184-6Innoviva Specialty Therapeutics. Innoviva Specialty Therapeutics announces distribution and licensing agreement with Dr. Reddy\u2019s for XACDURO in select international markets. Published June 16, 2026. Accessed October 26, 2026. <a href=\"https:\/\/investor.inva.com\/node\/21156\/pdf\" rel=\"nofollow noreferrer noopener\" target=\"_self\">https:\/\/investor.inva.com\/node\/21156\/pdf<\/a> <\/p>\n","protected":false},"excerpt":{"rendered":"David Altarac, MD, chief medical officer at Innoviva Specialty Therapeutics, which markets sulbactam-durlobactam in the United States, spoke&hellip;\n","protected":false},"author":2,"featured_media":666980,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[103,61,60],"class_list":["post-666979","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-health","tag-ie","tag-ireland"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/666979","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=666979"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/666979\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/666980"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=666979"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=666979"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=666979"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}